We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

7 hedge funds and large institutions have $657K invested in Xenetic Biosciences in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding

Funds holding: 6 → 7 (+1)

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

4% less capital invested

Capital invested by funds: $682K → $657K (-$24.2K)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$5.95K
2
UBS Group
UBS Group
Switzerland
+$4.25K
3
PAM
Panagora Asset Management
Massachusetts
+$3.97K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
1
Royal Bank of Canada
Ontario, Canada
$621K – – –
PAM
2
Panagora Asset Management
Massachusetts
$16K +$3.97K +14 +25%
UBS Group
3
UBS Group
Switzerland
$7K +$4.25K +15 +94%
RE
4
RBC Europe
United Kingdom
$4.3K – – –
Morgan Stanley
5
Morgan Stanley
New York
$4K – – –
Deutsche Bank
6
Deutsche Bank
Germany
$4K +$5.95K +21 New
OIA
7
OneDigital Investment Advisors
Kansas
$1K – – –

XBIO Hedge Fund Activity: Q4 2017 in Review

7 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2017, worth a combined $657K — down 3.6% from $682K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XBIO positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Deutsche Bank, opening a new position worth an estimated $5.95K.

  • 7 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2017, up from 6 in Q3 2017.
  • Funds reported $657K of Xenetic Biosciences stock for Q4 2017, down 3.6% quarter-over-quarter.
  • 1 fund opened new Xenetic Biosciences positions in Q4 2017 and 0 closed out, a net change of +1 holder.
  • The largest Xenetic Biosciences buyer in Q4 2017 was Deutsche Bank, an estimated $5.95K added.

Based on aggregated 13F filings for Q4 2017.